On Dec 12, 2018 Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX) Sellers Increased Their Shorts By 10.89%

BioLineRx Ltd. (NASDAQ:BLRX) Corporate Logo

Change of 10.89% for Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX)’s short interest was noted. It was announced in December by FINRA the 1.46M short interest on BLRX. Previously was reported up change of 10.89% from 1.31 million shares. With Average volume 490,000, BLRX’s previous position will take 3 days to restore. Biolinerx LTD. – American Depositary Shares float short is 2.19%.

The stock decreased 1.21% or $0.008 during the last trading session, reaching $0.652.BioLineRx Ltd. has volume of 475,351 shares. Since December 12, 2017 BLRX has declined 40.10% and is downtrending. BLRX underperformed the S&P 500 by 40.10%.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.The company has $79.09 million market cap. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions.Last it reported negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

For more BioLineRx Ltd. (NASDAQ:BLRX) news posted briefly go to: Seekingalpha.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Benzinga.com. The titles are as follows: “BioLineRx launches Phase 1/2a study of AGI-134 in solid tumors – Seeking Alpha” posted on August 01, 2018, “VTVT Abuzz, TRVN Faces FDA Panel Next Week, BLRX Awaits Data In Oct. – Nasdaq” on October 03, 2018, “Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…) – Nasdaq” with a publish date: October 16, 2018, “Pre-Market Earnings Report for August 13, 2018 : SYY, TSG, HQCL, JKS, BLRX, EAST, SPCB – Nasdaq” and the last “22 Stocks Moving In Friday’s Pre-Market Session – Benzinga” with publication date: October 19, 2018.

BioLineRx Ltd. (NASDAQ:BLRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.